The anti-endotoxin agent, taurolidine, potentially reduces ischaemia-reperfusion injury through its metabolite taurine

An investigation into the efficacy of the anti-endotoxin agent, taurolidine in the attenuation of the post-reperfusion sequelae in patients subjected to cardio-pulmonary bypass: a double-blinded randomised clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN58678663

Enrollment

Registered

2009-07-21

Start date

1999-01-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischaemia-reperfusion injury Injury, Occupational Diseases, Poisoning Complications following infusion, transfusion and therapeutic injection

Interventions

From induction of anaesthesia, patients were administered 250 ml of 2% taurolidine or normal saline twice daily intravenously for 3 doses in total.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients (aged greater than or equal to 18 years, either sex) undergoing elective coronary artery bypass grafting 2. Left ventricular ejection fraction greater than 30% (affects likelihood of developing infection post-operatively for various reasons including increased inotropic support requirements, longer intensive care unit [ICU] stay, delayed mobilisation, and delayed removal of urinary catheters and intravenous lines) 3. Normal pulmonary function tests (affects likelihood of developing respiratory complications post-operatively)

Exclusion criteria

Exclusion criteria: 1. Patients with diabetes mellitus (affects likelihood of developing infection post-operatively) 2. Patients taking angiotensin-converting enzyme inhibitors (affects potential to reduce reperfusion injury by acting on leukocytes) 3. Patients taking steroids (more prone to developing infection) 4. Patients with chronic arrhythmias

Design outcomes

Primary

Measure	Time frame
Cytokines interleukin-6 (IL-6) and interleukin-10 (IL-10), measured immediately pre-operatively, at aortic unclamping, two, six and 24-hours post-unclamping	—

Secondary

Measure	Time frame
1. CD11b and CD14 receptor expression, measured immediately pre-operatively, at aortic unclamping, two, six and 24-hours post-unclamping 2. Respiratory burst and phagocytosis of circulating neutrophils, measured immediately pre-operatively, at aortic unclamping, two, six and 24-hours post-unclamping 3. Plasma lipopolysaccharide (LPS), measured immediately pre-operatively, at aortic unclamping, two, six and 24-hours post-unclamping 4. Arrhythmias, analysed intra-operatively and daily up until hospital discharge 5. Complications, analysed intra-operatively and daily up until hospital discharge	—

Measure

Time frame

1. CD11b and CD14 receptor expression, measured immediately pre-operatively, at aortic unclamping, two, six and 24-hours post-unclamping 2. Respiratory burst and phagocytosis of circulating neutrophils, measured immediately pre-operatively, at aortic unclamping, two, six and 24-hours post-unclamping 3. Plasma lipopolysaccharide (LPS), measured immediately pre-operatively, at aortic unclamping, two, six and 24-hours post-unclamping 4. Arrhythmias, analysed intra-operatively and daily up until hospital discharge 5. Complications, analysed intra-operatively and daily up until hospital discharge

—

Countries

Ireland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026